“KaloBios Pharmaceuticals Inc. KBIO, +75.48% said late Thursday that Martin Shkreli, founder and head of Turing Pharmaceuticals AG, has become its chief executive after he led an investor group that has purchased a 70% stake in the company. Shkreli stirred controversy in recent weeks by acquiring
“Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients”
“Positive results By week 24, patients reported that the higher 12 DU dose HDM SLIT-tablet improved nose symptoms by 49%, and eye symptoms by 68%, compared with placebo. Nose and eye symptoms also improved with the 6 DU dose HDM tablet, but to a lesser extent.”
“today announced the publication of results from its phase 3 clinical trial of aripiprazole lauroxil for the treatment of schizophrenia in the Journal of Clinical Psychiatry. Data from the trial showed that multiple dose strengths of aripiprazole lauroxil administered once monthly demonstrated sta
“- La Jolla Pharmaceutical Company LJPC, -14.91% (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced a reprioritization of its product development programs. A
“- Prana Biotechnology(asx:PBT) PRAN, +1.71% is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the Europea
“Global Trials Show Addition of Medtronic’s Solitaire™ Device Stent Thrombectomy Procedure in Treatment of Acute Ischemic Stroke Improves Neurological Outcomes”
“Radlink, Inc., an emerging global leader in advanced medical imaging technology, announced today that it has signed an exclusive worldwide sales agency agreement with Johnson & Johnson subsidiary DePuy Synthes Companies. The contractual partnership provides for the exclusive worldwide distributio
“AMRI AMRI, +0.00% announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredient
“Ohr Pharmaceutical, Inc. OHRP, -68.61% an ophthalmology research and development company, today announced the topline results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-re
“Zogenix, Inc. ZGNX, +2.29% a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday™ multi-dose Phase 1b clinical study. Relday is a proprietary, long-ac
“a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a Phase 2 clinical trial evaluating AuriProTM for the treatment of
“Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Sovaldi® (sofosbuvir), a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis. Sovaldi is i